In gaining FDA approval, the insulin glargine product Semglee receives automatic status as a biologic under the Biologics Price Competition and Innovation Act (BPCIA), although it was approved as a 505(b)(2) product under the Food Drug and Cosmetic Act. Semglee becomes the first insulin glargine under the 351(a) pathway.
The FDA has approved an insulin glargine (Semglee) under the generic 505(b)(2) New Drug Application pathway, and the drug automatically is deemed a biologic under section 351(a) of the Public Health Service Act of the Biologics Price Competition and Innovation Act (BPCIA), based on a policy enacted March 23, 2020. The drug references Sanofi’s Lantus.
Mylan and Biocon Biologics, which co-developed the agent, said they intend to seek “interchangeable” status for it, meaning pharmacists could fill prescriptions with Semglee without consulting the prescribing physician.
Semglee is approved in vial and and prefilled pen applications to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. “Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications,” Mylan and Biocon said in a statement.
"This approval is an important milestone, first and foremost for the millions of patients living with diabetes in the United States as we seek to expand their access to insulin through more affordable treatment options,” said Mylan CEO Heather Bresch. “It's also another milestone for Mylan as we continue to leverage our scientific, commercial, manufacturing and regulatory expertise to benefit patients, and as we enhance our portfolio with increasingly complex and higher value-chain products, like insulin.”
“We look forward to making this product available to patients in the United States as soon as possible," Mylan President Rajiv Malik said.
Mylan and Biocon said the product remains “at risk” of further litigation.
“Favorable judgments on all remaining patent claims asserted by Sanofi against Mylan's insulin glargine products have been obtained. Although Sanofi may seek certain appeals of those judgments, Mylan is confident they will not affect commercialization plans,” the companies said in the statement.
Lantus revenue for the 12 months ending April 30, 2020, was roughly $6 billion, according to Mylan and Biocon.
In October, Biocon and Mylan launched Semglee in Australia. The country has allowed the product to be substituted at the pharmacy level without consulting with the prescribing physician.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials
February 10th 2024The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.
Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings
January 23rd 2024Samsung Bioepis’ Biosimilar Market Report for the first quarter of 2024 chronicles some major market trends, including which treatment spaces have quicker uptake than others, highlighting missed opportunities for savings as well as the 1-year experience of adalimumab biosimilar competition in the US.
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
January 18th 2024The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
January 10th 2024IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.